GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Cube Labs SpA (MIL:CUBE) » Definitions » EBITDA Margin %

Cube Labs SpA (MIL:CUBE) EBITDA Margin % : -27.13% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cube Labs SpA EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cube Labs SpA's EBITDA for the six months ended in Jun. 2024 was €-0.28 Mil. Cube Labs SpA's Revenue for the six months ended in Jun. 2024 was €1.03 Mil. Therefore, Cube Labs SpA's EBITDA margin for the quarter that ended in Jun. 2024 was -27.13%.


Cube Labs SpA EBITDA Margin % Historical Data

The historical data trend for Cube Labs SpA's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cube Labs SpA EBITDA Margin % Chart

Cube Labs SpA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial 41.02 35.26 36.90 5.43 -24.50

Cube Labs SpA Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.73 -3.85 -26.72 -22.59 -27.13

Competitive Comparison of Cube Labs SpA's EBITDA Margin %

For the Asset Management subindustry, Cube Labs SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cube Labs SpA's EBITDA Margin % Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Cube Labs SpA's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cube Labs SpA's EBITDA Margin % falls into.


;
;

Cube Labs SpA EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cube Labs SpA's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-0.401/1.637
=-24.50 %

Cube Labs SpA's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.28/1.032
=-27.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cube Labs SpA  (MIL:CUBE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cube Labs SpA EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cube Labs SpA's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cube Labs SpA Business Description

Traded in Other Exchanges
N/A
Address
Giulio Caccini, 1, Rome, ITA, 00186
Cube Labs SpA operates as a venture builder that enables innovation in the healthcare technology space. The company is engaged in attracting sources of financing and providing entrepreneurial and operational support to the companies to develop healthcare technologies for the market.